NCCN Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion Premium The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients. Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy. Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test The genomic test is covered by Medicare for all men with localized prostate cancer being considered for treatment. NCCN Updates Guidelines Advising Against Using Polygenic Risk Scores Outside of Clinical Trials The guidelines caution that there are "significant limitations" in the interpretation of polygenic risk scores and they should not be used in patient management. Payor Policy Study Reveals Progress, Challenges in Liquid Biopsy Reimbursement Researchers concluded that there has been significant expansion of coverage for ctDNA assays over the past four years, but policies remain very heterogeneous and often limited. May 19, 2020 UMich Online Tool Aims to Improve Identification of Patients With Hereditary Cancer Risk Premium Mar 18, 2020 NCCN Backs Molecular Testing for Prostate Cancer Patients in Certain Risk Groups Dec 12, 2019 Universal Genetic Testing in Breast Cancer May Result in More Harm Than Good, Experts Worry Premium Dec 12, 2019 ACMG Suggests Docs Evaluate All Breast Cancer Patients for Genetic Risk Test Suitability Dec 4, 2019 NCCN Updates Genetic Testing Guidelines for Assessing Breast, Ovarian, Pancreatic Cancer Risk Nov 22, 2019 Racial Group Comparison Suggests More Research Needed on Prostate Cancer Recurrence Tests Premium Feb 22, 2019 Genomic Health Stresses Oncotype DX Value After Questions Raised by Recent Study Premium Feb 7, 2019 Prostate Cancer Patients With Germline Variants Were Often Not Covered by Testing Guidelines Oct 10, 2018 NCCN Update on Breast Cancer Genetic Testing Guidelines Marks Oncotype DX as 'Preferred' Test Aug 3, 2018 Post-TAILORx, Genomic Health Tightens Focus on International Expansion Premium May 30, 2018 Exact Sciences Shares Rise Sharply on New Colorectal Cancer Screening Recommendation Feb 20, 2018 NCCN Updated Prostate Cancer Guidelines Include New Genetic Testing Information Nov 2, 2016 MDxHealth Posts Sharp Rise in Q3 Revenues Mar 2, 2016 MDxHealth Prostate Cancer Diagnostic Included in NCCN Early Detection Guidelines Oct 27, 2014 NCCN Mentions Prolaris, Oncotype DX in Updated Prostate Cancer Guidelines Oct 24, 2014 NCCN Including Use of VeriStrat in NSCLC Guidelines Oct 16, 2013 MDxHealth's MGMT Dx May Benefit from NCCN Support for Assessing Methylation Status in Glioblastoma Premium Aug 16, 2012 Will Insurers Cover $700 for Myriad's Large Rearrangement Test Plus $3K for BRACAnalysis? Premium Jul 25, 2012 Following CLIA Lab Buy, Life Tech Jumps into MDx Space with Purchase of Pinpoint, Lung Cancer Dx Premium Apr 18, 2012 ALK Mutation Testing for NSCLC on the Rise among Oncologists, BioTrends Survey Finds Premium Load More Breaking News Canadian Healthcare Providers, Policymakers Value Different Aspects of Clinical Genomic Sequencing New Products Posted to GenomeWeb: Oxford Nanopore, Bio-Rad, NanoString, More People in the News at OraSure, Element Biosciences, Micronoma, More Guardant Health Files Motions to Dismiss, Change Venue in Illumina Patent Lawsuit In Brief This Week: SQI Diagnostics, T2 Biosystems, Enhanc3D, QuidelOrtho, More Illumina, Precision Health Research Singapore Partner for 100K Genomes Population Study The Scan Blend of Omicron With Delta The Associated Press reports that currently circulating Omicron variants have some features previously seen in the Delta variant. Limited Contrast The New York Times reports that there is a shortage of a contrast agent used for some medical scans. Pig Improvement Farmers in China are using genetics to improve their hog herds, according to Reuters. Science Papers Present Way to Molecularly Classify Prostate Cancer, Saliva-Based SARS-CoV-2 Test, More In Science this week: approach to molecularly classify prostate tumors, saliva-based test for SARS-CoV-2, and more.